Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.48 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29604746 | 1.00 | CYP2A6 (0.48) | CYP2A6ASIC3LOXL2MGLLBCL2L1 | |
| SCHEMBL2972310 | 0.98 | CYP2A6 (0.47) | CYP2A6ASIC3LOXL2MGLLBCL2L1 | |
| Thiophene SCHEMBL7069131 | 0.89 | CYP2A6 (0.41) | CYP2A6ASIC3LOXL2MGLLBCL2L1 | |
| SCHEMBL6651277 | 0.75 | CYP2A6 (0.48) | CYP2A6ASIC3LOXL2MGLLBCL2L1 | |
| SCHEMBL845603 | 0.74 | APP (0.63) | CYP2A6ASIC3LOXL2MGLLBCL2L1 | |
| SCHEMBL29732980 | 0.74 | APP (0.63) | CYP2A6ASIC3LOXL2MGLLBCL2L1 | |
| SCHEMBL29196258 | 0.73 | CYP2A6 (0.41) | CYP2A6LOXL2APPSIGMAR1 | |
| SCHEMBL5336284 | 0.73 | CYP2A6 (0.41) | CYP2A6LOXL2HDAC6 | |
| SCHEMBL734280 | 0.72 | CYP2A6 (0.50) | CYP2A6ASIC3LOXL2MGLLBCL2L1 | |
| SCHEMBL2150858 | 0.72 | APP (0.50) | CYP2A6ASIC3LOXL2MGLLBCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9597315-B2 | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments | EUTHYMICS BIOSCIENCE, INC. (US) | 2017-03-21 | — | — | US | claimed |
| CN-105492429-A | Heteroaryl inhibitors of SUMO activating enzyme | MILLENNIUM PHARM INC | 2016-04-13 | — | — | CN | claimed |
| US-20160022634-A1 | NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | ETHISMOS RESEARCH, INC. | 2016-01-28 | — | — | US | claimed |
| CN-105209457-A | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE DEUTSCHLAND | 2015-12-30 | — | — | CN | claimed |
| CN-103732583-B | TRPV4 antagonist | GLAXOSMITHKLINE LLC (GB) | 2015-12-23 | — | — | CN | claimed |
| EP-2167083-B1 | 1- HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | EUTHYMICS BIOSCIENCE INC (US) | 2015-10-28 | — | — | EP | claimed |
| US-9133159-B2 | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments | NEUROVANCE, INC. (US) | 2015-09-15 | — | — | US | claimed |
| CN-102482285-B | Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI SA | 2015-07-15 | — | — | CN | claimed |
| CN-102482286-B | Novel 1,2,3, 4-tetrahydropyrimidino {1,2-a } pyrimidin-6-one derivatives, their preparation and their medical use | SANOFI SA | 2015-07-15 | — | — | CN | claimed |
| CN-102153562-B | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC | 2015-05-13 | — | — | CN | claimed |
| US-20140303207-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments | NEUROVANCE, INC. (US) | 2014-10-09 | — | — | US | claimed |
| EP-2167083-A2 | NOVEL 1- HETEROARYL-3-AZABICYCLOÝ3.1.0¨HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DOV Pharmaceutical, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| WO-2008153937-A2 | NOVEL 1- HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DOV PHARMACEUTICAL, INC. (US) | 2008-12-18 | — | — | WO | claimed |
| EP-1444201-B1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LTD (GB) | 2007-09-12 | — | — | EP | claimed |
| EP-1778639-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| US-7179835-B2 | 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2007-02-20 | — | — | US | claimed |
| WO-2006020049-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20050004119-A1 | 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-01-06 | — | — | US | claimed |
| EP-1444201-A1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-08-11 | — | — | EP | claimed |
| WO-2003043981-A1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303207-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments | HTR3C, HTR2C, CNR1 | CYP2A6 87/4885ASIC3 3302/4885LOXL2 2533/4885 |
| US-20160022634-A1 | NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HTR3C, HTR2C, GRIN2C | CYP2A6 98/4885ASIC3 3190/4885LOXL2 2415/4885 |
| US-20050004119-A1 | 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | SERPINC1, F11, SERPINE1 | CYP2A6 866/4885ASIC3 2377/4885LOXL2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.